/CRDF

CRDF Stock - Cardiff Oncology, Inc.

Q: What is the analyst price target for CRDF?

Analyst price target information is not currently available for CRDF.

Q: What is CRDF's market cap?

Market capitalization information is not currently available for CRDF.

Healthcare|Biotechnology|NASDAQ

$2.57+2.80%

+$0.07 (+2.80%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.83

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CRDF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.35

52W High$4.99

52W Low$1.90

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$683,000	$488,000	$386,000	$359,000	$366,000
Gross Profit	$683,000	$488,000	$386,000	$359,000	$366,000
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-48,651,000	$-45,412,000	$-39,902,000	$-28,855,000	$-19,086,000
Net Income	$-45,431,000	$-41,441,000	$-38,704,000	$-28,291,000	$-19,307,000
Net Margin	-6651.7%	-8492.0%	-10026.9%	-7880.5%	-5275.1%
EPS	$-0.95	$-0.93	$-0.89	$-0.73	$-1.08

Company Overview

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

67%

Hold / Neutral

33%

Sell / Underperform

Analyst Consensus🟡 Mixed

2 Bullish1 Neutral/Bearish

Price Targets

$10

Average Target

↑ 295.6% Upside

Now

Low

$10

Average

$19

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 8th 2025	Ladenburg Thalmann	Initiation	Buy	$19
June 24th 2025	Jefferies	Initiation	Hold	$3.5
September 6th 2024	Craig Hallum	Initiation	Buy	$8

Earnings History & Surprises

CRDF

Beat Rate

56%

Last 18 quarters

Avg Surprise

+3.8%

EPS vs Estimate

Beats / Misses

10/7

1 met exactly

Latest EPS

$-0.17

Q4 2025

EPS Surprise History

Q1 24

+19.2%

$-0.21vs$-0.26

Q2 24

+12.0%

$-0.22vs$-0.25

Q3 24

-4.0%

$-0.26vs$-0.25

Q4 24

+7.4%

$-0.25vs$-0.27

Q1 25

+19.2%

$-0.21vs$-0.26

Q2 25

-5.3%

$-0.20vs$-0.19

Q3 25

-10.5%

$-0.21vs$-0.19

Q4 25

+15.0%

$-0.17vs$-0.20

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 26, 2026	$-0.18	—	—	—
Q4 2025	Nov 6, 2025	$-0.20	$-0.17	+15.0%	✓ BEAT
Q3 2025	Jul 29, 2025	$-0.19	$-0.21	-10.5%	✗ MISS
Q2 2025	May 8, 2025	$-0.19	$-0.20	-5.3%	✗ MISS
Q1 2025	Feb 27, 2025	$-0.26	$-0.21	+19.2%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.27	$-0.25	+7.4%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.25	$-0.26	-4.0%	✗ MISS
Q2 2024	May 2, 2024	$-0.25	$-0.22	+12.0%	✓ BEAT
Q1 2024	Feb 29, 2024	$-0.26	$-0.21	+19.2%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.29	$-0.22	+24.1%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.27	$-0.25	+7.4%	✓ BEAT
Q2 2023	May 4, 2023	$-0.23	$-0.25	-8.7%	✗ MISS
Q1 2023	Mar 2, 2023	$-0.25	$-0.20	+20.0%	✓ BEAT
Q4 2022	Nov 3, 2022	$-0.27	$-0.20	+25.9%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.25	$-0.24	+4.0%	✓ BEAT
Q2 2022	May 5, 2022	$-0.23	$-0.25	-8.7%	✗ MISS
Q1 2022	Feb 24, 2022	$-0.17	$-0.23	-35.3%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.17	$-0.17	0.0%	= MET
Q3 2021	Aug 5, 2021	$-0.15	$-0.17	-13.3%	✗ MISS

Frequently Asked Questions about CRDF

What is CRDF's current stock price?

Cardiff Oncology, Inc. (CRDF) is currently trading at $2.57 per share. The stock has moved +2.80% today.

What is the analyst price target for CRDF?

No analyst price targets are currently available for this stock.

What sector is Cardiff Oncology, Inc. in?

Cardiff Oncology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CRDF's market cap?

Cardiff Oncology, Inc. has a market capitalization of $0.17 billion, making it a small-cap company.

Does CRDF pay dividends?

No, Cardiff Oncology, Inc. does not currently pay a dividend to shareholders.